Top of the morning, and what a cold one it is. A bit of an arctic freeze has descended upon many of us on this side of the pond, but we are keeping warm thanks to — you guessed it — multiple cups of stimulation. This is why coffee kettles were invented, after all. So fire it up, pour a hot one, and please enjoy the tidbits below. Hope your day goes well and you remain toasty …

When two generic drug makers scrambled last July to recall hundreds of lots of the valsartan blood pressure drug, a third company unaffected by the recall saw a “one-off opportunity” to significantly increase prices, USA Today writes. Teva Pharmaceutical (TEVA) and Prinston Pharmaceutical recalled the meds after testing revealed small amounts of a probable carcinogen, but the same drugs produced by Alembic Pharmaceuticals did not show contamination. And Alembic more than tripled the price of 17 of its own formulations of valsartan, from 329 percent to 469 percent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy